Gene Therapies for Ageing
Key Takeaways
- Gene therapies can introduce, silence, or edit genetic instructions, but ageing applications remain mostly experimental.
- Telomerase reverse transcriptase (TERT), follistatin, and Klotho are studied as mechanistic candidates in animal models and disease-focused translational research.
- Delivery vectors such as adeno-associated viruses (AAVs) and lentiviruses face payload, targeting, redosing, and immunogenicity limits.
- Genome-editing approaches may eventually support more precise interventions, but multiplex age-related applications remain early and speculative.
Why Gene Therapy Is Studied in Ageing Biology
Ageing is associated with processes such as macromolecular damage, telomere attrition, altered gene expression, and stem-cell dysfunction. Gene therapy is studied because it can change cellular instructions for longer periods than many small molecules. That does not mean the approach is proven for human ageing: durability, tissue targeting, reversibility, immune reactions, and long-term cancer risk remain central uncertainties.
Key Gene Therapy Targets
| Therapeutic Gene | Mechanism | Translational Progress and Results |
|---|---|---|
| Follistatin (FST) | Myostatin inhibitor. By blocking myostatin signalling, follistatin can increase muscle mass in some experimental contexts. | Supported by animal and disease-model research, including work relevant to muscle disorders. Evidence for general age-related use in humans is not established. |
| Telomerase (TERT) | Expresses the TERT enzyme, which helps maintain telomeres in some cellular contexts. | Mouse studies have reported delayed ageing phenotypes and longer lifespan after TERT gene delivery. Human relevance is uncertain, especially because telomerase biology intersects with cancer risk. |
| Klotho | Membrane-bound and circulating protein linked to phosphate metabolism, renal biology, insulin signalling, and neural function. | Overexpression has extended lifespan in some mouse models, but dosage, tissue specificity, and vector design remain unresolved for human translation. |
Vectors and Delivery Challenges
The vehicle carrying the genetic instruction is often the limiting factor for safety and efficacy.
- Adeno-associated viruses (AAVs): Commonly used for in vivo delivery because they can reach non-dividing cells and usually remain episomal. Their payload is small, tissue targeting is imperfect, and neutralizing antibodies can limit redosing.
- Cytomegalovirus-derived vectors: CMV-based systems are being explored because they may carry larger genetic payloads than AAVs. They remain less established for ageing applications and require careful safety evaluation.
Different Strategies Require Different Evidence
“Gene therapy” covers interventions with importantly different risk profiles. Gene addition supplies an extra coding sequence, as in experimental AAV delivery of TERT or follistatin. Gene silencing aims to reduce a selected transcript, while genome editing makes a sequence-level change. These approaches differ in permanence, reversibility, off-target risk, and the consequences of reaching the wrong tissue. A result from one platform therefore cannot be treated as evidence for the others.
Target choice also determines what a study can establish. The TERT mouse experiment tested a defined vector, promoter, dose, species, and treatment age; it did not demonstrate that telomerase delivery is safe across human lifetimes. [1] Follistatin delivery increased muscle size and strength in a small non-human-primate study, but the animals did not model general human ageing and the treatment was directed to muscle. [2] These studies support biological feasibility, not a broad claim that gene transfer slows ageing.
How Translational Studies Should Be Read
Useful studies should report where the vector travels, how many cells express the transgene, how long expression persists, and whether expression can be restricted or stopped. Safety assessment must extend beyond short-term adverse events to immune responses, organ toxicity, clonal expansion, and tumour surveillance. For an ageing indication, clinically meaningful outcomes would also need to be distinguished from intermediate measures such as transgene expression, muscle volume, telomere length, or molecular biomarkers. Durable improvement in function is a more demanding endpoint than evidence that the construct reached its target.
The Gap Between Mice and Men
Positive findings in mice do not automatically translate to human ageing. Larger bodies require different dosing, tissue distribution is harder to control, and immune or liver toxicity can become dose-limiting. Telomerase is especially difficult to interpret because longer telomere maintenance may support tissue renewal in some settings while also intersecting with cancer biology. For these reasons, gene therapy for ageing should be read as an experimental research area rather than an available longevity intervention.
References
- Bernardes de Jesus, B. et al. "Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer." EMBO Molecular Medicine (2012). https://doi.org/10.1002/emmm.201200245
- Kota, J. et al. "Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates." Science Translational Medicine (2009). https://pmc.ncbi.nlm.nih.gov/articles/PMC2852878/
This content is provided for academic reference only and does not constitute advice. Gene therapies for ageing are not approved as general anti-ageing or longevity interventions. The relevant evidence should be interpreted through the specific model, indication, vector, dose, and endpoint studied.